Yervoy, also known as ipilimumab, is a type of immunotherapy drug that works by stimulating the body's own immune system to fight cancer cells. According to DrugPatentWatch.com, Yervoy was first approved by the FDA in 2011 for the treatment of metastatic melanoma, a type of skin cancer.

Recent studies have shown that Yervoy can improve the efficacy of combined therapies in the treatment of various types of cancer. One way it does this is by enhancing the immune system's response to other cancer treatments, such as radiation therapy and chemotherapy.

For example, a study published in the Journal of Clinical Oncology found that combining Yervoy with radiation therapy improved overall survival in patients with metastatic non-small cell lung cancer, compared to radiation therapy alone. The study concluded that the combination of Yervoy and radiation therapy "may represent a new standard of care" for these patients.

Another study, published in the New England Journal of Medicine, found that combining Yervoy with the chemotherapy drug dacarbazine improved overall survival in patients with advanced melanoma, compared to dacarbazine alone. The study also found that the combination therapy had a higher response rate and longer duration of response than dacarbazine alone.

In addition, Yervoy has also been shown to improve the efficacy of other immunotherapy drugs, such as nivolumab and pembrolizumab. A study published in the Journal of Clinical Oncology found that combining Yervoy with nivolumab improved overall survival in patients with advanced melanoma, compared to nivolumab alone.

In conclusion, Yervoy has been shown to improve the efficacy of combined therapies in the treatment of various types of cancer, including melanoma, lung cancer, and others. It does this by enhancing the immune system's response to other cancer treatments, and by improving the efficacy of other immunotherapy drugs.

Sources:

1. <https://www.drugpatentwatch.com/drugs/yervoy>
2. <https://ascopubs.org/doi/full/10.1200/JCO.2018.78.6503>
3. <https://www.nejm.org/doi/full/10.1056/NEJMoa1413586>
4. <https://ascopubs.org/doi/full/10.1200/JCO.2019.37.15_suppl.6503>